Vanda Pharmaceuticals
Yahoo Finance • 8 months ago
Vanda Pharmaceuticals announces the publication of an article on "The Efficacy of Tradipitant in Patients with Diabetic and Idiopathic Gastroparesis in Phase III Randomized Placebo-Controlled Clinical Trial" in the Clinical Gastroenterology and Hepatology Journal
WASHINGTON, Jan. 25, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the publication of an article titled "The Efficacy of Tradipitant in Patients with Diabetic and Idiopathic Gastroparesis in Phase I... Full story
Yahoo Finance • 11 months ago
Vanda Pharmaceuticals Reports Third Quarter 2023 Financial Results
Total revenues in the first nine months of 2023 were $147.4 million Vanda provides update on pipeline advancements and regulatory plans WASHINGTON, Nov. 8, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today anno... Full story
Yahoo Finance • last year
Q1 2023 Vanda Pharmaceuticals Inc Earnings Call
Participants Kevin Patrick Moran; Senior VP, CFO & Treasurer; Vanda Pharmaceuticals Inc. Mihael H. Polymeropoulos; Founder, President, CEO & Chairman of The Board; Vanda Pharmaceuticals Inc. Timothy Williams; Senior VP, General Counsel... Full story
Yahoo Finance • 2 years ago
VANDA PHARMACEUTICALS ANNOUNCES NOTICE OF OPPORTUNITY FOR AN FDA HEARING ON THE sNDA FOR HETLIOZ® IN JET LAG DISORDER
WASHINGTON, Sept. 7, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the notice of opportunity for an FDA hearing on Vanda's Supplemental New Drug Application (sNDA) for HETLIOZ® (tasimelteon) to trea... Full story
Yahoo Finance • 2 years ago
Vanda Pharmaceuticals to Announce First Quarter 2022 Financial Results on May 5, 2022
Conference Call and Webcast to Follow WASHINGTON, April 28, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the first quarter 2022 on Thursday, May 5, 2022, after the mark... Full story
